BioSpace News Archive

Business

Voyager Rolls on as Novartis Selects Two of Three CNS Targets

Voyager Therapeutics unlocked a potential $600 million plus $25 million upfront as Novartis exercised its option to leverage the company’s capsids against two undisclosed neurologic disease targets.

March 6, 2023
·
2 min read
·
Heather McKenzie
Career Advice

How to Nail Virtual Interviews & Networking Events

Here are some tips to help you nail virtual interviews and networking events so you can be prepared for BioSpace’s Virtual Talent Connect on March 9.

March 6, 2023
·
4 min read
·
Rosemary Scott
Drug Development

Full Results from Esperion’s Cholesterol Drug Fail to Impress Investors

With the results from the CLEAR outcomes study, Esperion is poised for a major inflection in sales and is targeting blockbuster status, said CEO Sheldon Koenig on an investor call Monday.

March 6, 2023
·
2 min read
·
Kate Goodwin
Drug Development

Incyte Abandons Phase III Trial for Myelofibrosis Treatment

Incyte Corporation’s Phase III LIMBER-304 clinical trial has come to an end following a third-party investigation that forecasted poor results.

March 6, 2023
·
1 min read
·
Hayleigh Evans
Policy

FDA Sets July Decision Date for Full Approval of Leqembi

The FDA set a decision date of July 6, 2023 for Eisai and Biogen’s recently approved Alzheimer’s drug, Leqembi, Eisai announced Monday.

March 6, 2023
·
2 min read
·
Kate Goodwin
Evonik and BellaSeno advance commercialization of 3D-printed, bioresorbable implants

Evonik and BellaSeno, a developer of 3D-printed absorbable scaffolds, are working together to commercialize innovative 3D-printed scaffolds for bone regeneration.

March 6, 2023
·
4 min read
Policy

Sooma Medical Receives FDA Breakthrough Device Designation for Its Innovative At-Home Depression Treatment Device

Sooma Medical, a medical device company based in Finland, has been granted Breakthrough Device designation by the U.S. Food and Drug Administration for its portable, patient-administered neuromodulation device to treat depression.

March 6, 2023
·
2 min read
Business

EyeBio Announces First Asset in Innovative Pipeline of Retinal Disease Treatments and Appoints Industry Leaders to Executive Team

Eyebiotech Limited announced several appointments to its executive team, featuring prominent industry leaders who are highly skilled in the development of multi-specific antibodies and ophthalmic drugs.

March 6, 2023
·
7 min read
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

Adaptimmune Therapeutics plc (Nasdaq: ADAP) and TCR² Therapeutics Inc. (Nasdaq: TCRR), today announced entry into a definitive agreement under which Adaptimmune will combine with TCR² in an all-stock transaction to create a preeminent cell therapy company focused on treating solid tumors

March 6, 2023
·
21 min read
Business

Science 37 Reports Fourth Quarter and Full Year 2022 Financial Results

Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”), the industry-leading Metasite™, today reported its financial results for the quarter and full year ended December 31, 2022.

March 6, 2023
·
18 min read